Drugs made with botulinum toxin may offer an alternative to opioids, a study in mice finds
Painkillers crafted with a part of the wrinkle-smoothing drug Botox provide long-term pain relief in mice.
Researchers added the modified Botox to molecules that target pain-messaging nerve cells. Mice given a single spinal injection of the new drugs showed signs of pain relief for the full duration of the experiments, around three weeks, researchers report online July 18 in Science Translational Medicine. Such painkillers could potentially one day be developed for humans as alternatives to more addictive drugs, such as opioids.
Created by the bacterium Clostridium botulinum, botulinum toxin causes the food poisoning disease botulism. Botox, which is made from the toxin, is often injected into people to iron out worry lines and has been used to treat conditions that involve overactive muscles, such as repetitive neck spasms or overactive bladder (SN: 4/5/08, p. 213). The toxin has also been used to reduce the frequency of migraines.
Biochemist Bazbek Davletov of the University of Sheffield in England and colleagues focused on botulinum toxin because it can stop certain nerve cells from communicating with one another for up to five months with each injection. And “you locally inject less than a millionth of a gram, which is helpful to avoid any immune response,” he says.
Davletov and colleagues created their new drugs with a process he describes as a “molecular Lego system.” Taking the part of the botulinum toxin that blocks nerve cells from sending messages, the team attached the piece to one of two molecules that target neurons that relay pain information. The researchers removed the part of the toxin, found in Botox, that binds to muscle-controlling nerve cells.
In the new study, the scientists injected SP-BOT, a botulinum toxin-based pain reliever they’d made previously, into the spinal fluid of male mice with pain due to nerve damage. SP-BOT provided pain relief starting around three days after the injection and lasted through the rest of the experiment. In another experiment, SP-BOT also mollified pain from inflammation due to a different injury.
The researchers also created a new formula, called DERM-BOT, which targets nerve cell opioid receptors with dermorphin, a natural opioid secreted from the skin of a South American tree frog. DERM-BOT injected in mice with nerve damage kicked in right away and then provided pain relief to the rodents for over three weeks. The drug was also likewise effective in lessening pain from injuries that produced inflammation.
The team gauged the painkillers’ effectiveness by poking the animals’ paws with plastic filaments of different diameters. Mice in pain withdrew their paws from the finer filaments, Davletov says, while mice with pain relief didn’t withdraw until prodded by the thicker filaments, the same behavior seen in healthy mice.
Injecting the drugs into healthy mice caused no mobility issues, the researchers found, indicating that the drugs did not target muscle-controlling nerve cells as Botox does.
Neuroscientist Luana Colloca of the University of Maryland, Baltimore, who was not part of the study, says the drugs are promising candidates for further research in humans. Short-term painkillers, including morphine, may require multiple daily doses, and a body can build up tolerance and require higher doses for relief, she says. “One single administration lasting for several months can reduce the risk of dependence and addiction.”
But the drugs should be tested in female animals, Colloca adds. “We truly need to know if this data apply also to women in pain.”
M. Maiarù et al. Selective neuronal silencing using synthetic botulinum molecules alleviates chronic pain in mice. Science Translational Medicine. Published online July 18, 2018. doi/10.1126/scitranslmed.aar7384.
B. Bower. Botox injections put a crease in emotional evaluations. Science News. Vol. 178, July 31, 2010, p. 8.
R. Ehrenberg. Traveling toxin: Botox may hitch a ride on nerve cells. Science News. Vol. 173, April 5, 2008, p. 213.